Lincoln Pharmaceuticals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.76×	0.76×	0.75×	0.76×	0.73×
	1.52×	1.39×	1.23×	1.37×	1.26×
	11.7%	12.4%	14.2%	15.4%	15.7%
	0.80×	0.80×	0.83×	0.90×	0.95×
	1.19×	1.18×	1.19×	1.18×	1.17×
	12.8%	12.3%	13.0%	17.1%	15.9%
	12.3%	12.3%	13.0%	17.0%	14.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

LINCOLN₹507.90

Lincoln Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersSIGACHI THEMISMED BAJAJHCARE AMRUTANJANJAGSNPHARM WANBURY AHCLMcap ₹1,017 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.73	0.76	0.75	0.76	0.76
Interest Burden (Pretax/EBIT) ×	1.26	1.37	1.23	1.39	1.52
EBIT Margin %	15.68	15.38	14.22	12.40	11.69
Asset Turnover ×	0.95	0.90	0.83	0.80	0.80
Financial Leverage (Assets/Equity) ×	1.17	1.18	1.19	1.18	1.19
ROE (5-step product, year-end total equity) %	15.87	17.09	13.01	12.32	12.75
ROE (owners' profit / average owners' equity) %	14.51	17.04	13.02	12.30	12.30

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.